Shares

9 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2022

May 16, 2022

SELL
$14.54 - $21.5 $500,946 - $740,739
-34,453 Closed
0 $0
Q4 2021

Feb 14, 2022

BUY
$20.24 - $36.01 $697,328 - $1.24 Million
34,453 New
34,453 $715,000
Q3 2021

Nov 15, 2021

SELL
$26.01 - $38.22 $331,679 - $487,381
-12,752 Closed
0 $0
Q2 2021

Aug 16, 2021

BUY
$29.97 - $37.17 $382,177 - $473,991
12,752 New
12,752 $393,000
Q1 2021

May 17, 2021

SELL
$29.24 - $42.03 $319,534 - $459,303
-10,928 Closed
0 $0
Q4 2020

Feb 16, 2021

BUY
$35.35 - $50.67 $386,304 - $553,721
10,928 New
10,928 $395,000
Q3 2020

Nov 16, 2020

SELL
$35.98 - $47.66 $423,196 - $560,576
-11,762 Closed
0 $0
Q2 2020

Aug 14, 2020

SELL
$45.06 - $67.74 $30,325 - $45,589
-673 Reduced 5.41%
11,762 $530,000
Q1 2020

May 15, 2020

BUY
$40.01 - $73.97 $497,524 - $919,816
12,435 New
12,435 $590,000

Others Institutions Holding QURE

About uniQure N.V.


  • Ticker QURE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,729,100
  • Market Cap $300M
  • Description
  • uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...
More about QURE
Track This Portfolio

Track Twinbeech Capital LP Portfolio

Follow Twinbeech Capital LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Twinbeech Capital LP, based on Form 13F filings with the SEC.

News

Stay updated on Twinbeech Capital LP with notifications on news.